USPTO serial 79358840
TSURE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 23, 2024
- Examiner
- CARR, PATRICK C
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with TSURE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | diagnostic reagents for medical use; reagents for use in medical genetic testing; medical diagnostic products for bacteriological cultures, namely, medical diagnostic reagents; chemical preparations for pharmaceutical use, namely, for treating infectious diseases, inflammatory and neoplastic diseases, digestive diseases, respiratory diseases, circulatory diseases, immune system diseases; chemical preparations for medical use, namely, for treating infectious diseases, inflammatory and neoplastic diseases, digestive diseases, respiratory diseases, circulatory diseases, immune system diseases; diagnostic preparations for medical use; diagnostic kits for medical diagnostic purposes consisting of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, for the detection of cancer, infectious diseases, inflammatory disorders and oncological disorders; purified biochemicals, namely, protein arrays, fluorescent enzymes and dyes for use as reagents for medical diagnostics; chemical reagents for medical and veterinary use; biochemical preparations for medical use being chemical preparations for the diagnosis of pregnancy; diagnostic biomarking reagents for medical use; all of the aforementioned goods are not for use with infusion sets; ointments for pharmaceutical use being antibiotic ointments; antibiotic ointments; anti-inflammatory ointments; medicinal ointments for treating dermatological conditions; food for babies; dietary supplements for humans and animals for the mouth to be taken in the nature of tablets, capsules and gel capsules; dental waxes | ACTIVE | — |
| 010 | blood testing apparatus; x-ray diagnostic apparatus; testing apparatus for medical use, namely, genetic testing apparatus for medical purposes; diagnostic imaging apparatus for medical use, namely, electromagnetic medical diagnostic imaging apparatus; apparatus for testing bacteria and viruses, namely, medical diagnostic apparatus for testing for viruses and bacteria; DNA extraction and purification apparatus for medical use, namely, apparatus for DNA testing for medical purposes; medical apparatus and instruments for RNA analysis, other than for dental use, namely, apparatus for RNA testing for medical purposes; body composition analyzers for medical use; diagnostic apparatus for medical and veterinary use, in particular for detecting nucleic acid molecules in a sample, in particular in a patient sample, namely, medical apparatus and instruments for diagnostic use for testing for hereditary diseases, infectious diseases, inflammatory and neoplastic diseases, digestive diseases, respiratory diseases, circulatory diseases, immune system diseases; analysis devices for identification of bacteria for medical use, namely, medical instruments for analysing and identifying bacteria; DNA and RNA testing apparatus for medical use; genetic testing apparatus for medical use; medical devices, namely, nucleic acid analyzer for medical diagnostics, namely, medical apparatus and instruments for diagnostic use for testing for hereditary diseases, infectious diseases, inflammatory and neoplastic diseases, digestive diseases, respiratory diseases, circulatory diseases, immune system diseases; immunochemical testing apparatus for medical use; all of the aforementioned goods do not consist of infusion sets, and are not for use with infusion sets | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SANSURE BIOTECH FRANCE
- Other trademarks owned by SANSURE BIOTECH FRANCE
- Other trademarks owned by SANSURE BIOTECH FRANCE
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named TSURE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 7, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 25, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 7, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 6, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 23, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 23, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 23, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 30, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 7, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 7, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| May 8, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| May 7, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 7, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 17, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 17, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 17, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 10, 2024 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Apr 1, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 15, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 15, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 15, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 13, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 13, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 13, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 13, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 13, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 12, 2024 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jan 2, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 2, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 2, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 27, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 25, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 25, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 4, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 11, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 11, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 7, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 6, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 28, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 7, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 3, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 30, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |